← Back to patent-cliff list
帕利普韦/奥比他韦/利托那韦
Tier C — Watch / tradeParitaprevir/Ombitasvir/Ritonavir
艾伯维
Originator
2015
First approval
-
Expiry (public)
No sales data
Peak sales
化学药
Type
Targets：HIV-1 protease、NS5A、NS3/NS4A
Brand：维建乐、Technivie、Viekirax、Qurevo
Indications (approved)：慢性丙型肝炎、丙型肝炎
Regional status
US
撤市
EU
撤市
China
批准上市
2017-09-20
Japan
批准上市
2015-09-28
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Paritaprevir/Ombitasvir/Ritonavir?
Approved indications include: 慢性丙型肝炎, 丙型肝炎.
When does the Paritaprevir/Ombitasvir/Ritonavir patent expire?
No public expiry year is available for Paritaprevir/Ombitasvir/Ritonavir yet; this page updates once verified.
How do I get a quote for Paritaprevir/Ombitasvir/Ritonavir intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-24